Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILs-NSCLC in previously treated NSCLC
NCT04069936Phase 2Terminated
- Sponsor
- WindMIL Therapeutics
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MILs-NSCLC in non-small cell lung cancer (NSCLC), sponsored by WindMIL Therapeutics. Primary endpoints: Adverse Events per NCI-CTCAE v5.0, Serious Adverse Events per NCI-CTCAE v5.0 and 1 more. Started Oct 2019; status: terminated.
02
Drugs
MILs-NSCLC
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04069936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069936.